ENTITY
Pharmaron Beijing

Pharmaron Beijing (3759 HK)

151
Analysis
Health CareChina
Pharmaron Beijing Co., Ltd. engages in discovery, development, and manufacturing spectrum for small molecule drugs, cell therapies, and gene therapies as well as providing testing services for medical devices and clinic research. The Company offers laboratory, clinical development, chemistry manufactory and control, and other services. Pharmaron Beijing conducts businesses based in China.
more
21 Sep 2020 09:39

Pharmaron Buy Support

Pharmaron Beijing Co Ltd-H (3759 HK) displays a near term negative tactical bias from the 100 area for a pullback toward favorable risk to reward...

Share
16 Aug 2020 17:17

HSCI Index Rebalance - Stock Connect Flows Coming Up

The Hang Seng Indexes Company Limited (HSIL) announced the results of its review of the Hang Seng Family of Indexes post market close on 14 August....

Logo
484 Views
Share
06 Aug 2020 14:57

Tigermed IPO: Trading Debut

Hangzhou Tigermed Consulting (H) (3347 HK) is a global contract research organisation (CRO). Tigermed is the largest clinical CRO in China with a...

Logo
412 Views
Share
02 Aug 2020 09:20

Haier (1169 HK): Avatar Scrip Offer From Parent

Haier Electronics Group Co (1169 HK) (HEG) was briefly suspended pursuant to the Takeovers Code on the 19 December 2019, which was followed by...

Logo
534 Views
Share
27 Jul 2020 15:34

Tigermed (泰格医疗) A+H: Past A+H Listings Suggest Upside Might Be Limited

Tigermed, the largest China-based clinical CRO company, launched book building today to raise up to USD 1.4 bn to list in Hong Kong.  In our...

Logo
401 Views
Share
x